Monte Rosa Therapeutics, INC Schedule 13G passive stakes

Vestal Point Capital, LP, along with its Chief Investment Officer Ryan Wilder, has reported beneficial ownership of 5.4% of Monte Rosa Therapeutics, Inc. common stock.

T. Rowe Price Associates, Inc. has reported beneficial ownership of 10.5% of Monte Rosa Therapeutics Inc.'s common stock as of June 30, 2026.

Biotechnology Value Fund and its affiliates have reported a 6.3% beneficial ownership stake in Monte Rosa Therapeutics, Inc. as of March 31, 2026.

Dimension Management and associated entities have filed a Schedule 13G reporting an 8.1% beneficial ownership stake in Monte Rosa Therapeutics, Inc.

Dimension Capital I, L.P. and its affiliated entities have reported a beneficial ownership of 8.7% in Monte Rosa Therapeutics, Inc. common stock.

T. Rowe Price Associates, Inc. has filed an amendment to disclose its beneficial ownership of 7.5% of Monte Rosa Therapeutics Inc. common stock.

Avoro Capital Advisors and Behzad Aghazadeh have reported a 0% beneficial ownership stake in Monte Rosa Therapeutics, Inc. as of September 30, 2025.

The Vanguard Group reported a 4.83% beneficial ownership stake in Monte Rosa Therapeutics Inc. common stock as of September 30, 2025.

TCG Crossover Funds and Chen Yu have disclosed a combined beneficial ownership of 7.2% in Monte Rosa Therapeutics, Inc., totaling 4,427,705 shares.

Dimension Capital and its affiliates have reported a 7.7% passive ownership stake in Monte Rosa Therapeutics, Inc., holding 4,757,563 common shares.

Avoro Capital Advisors and Behzad Aghazadeh have disclosed a 6.1% beneficial ownership stake in Monte Rosa Therapeutics, holding 3,725,000 shares for investment purposes.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.8% in Monte Rosa Therapeutics Inc. as of May 30, 2025.

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have collectively disclosed a beneficial ownership of 9.2% in Monte Rosa Therapeutics, Inc. as of March 31, 2025.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have collectively reported beneficial ownership exceeding 5% of Monte Rosa Therapeutics, Inc.'s common stock, indicating a passive investment.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have reported a beneficial ownership of 7.1% in Monte Rosa Therapeutics, Inc., holding 4,345,000 shares of common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.3% of Monte Rosa Therapeutics, Inc.'s common stock as of December 31, 2024.

A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P. and its affiliates, has disclosed a collective beneficial ownership of 7.2% in Monte Rosa Therapeutics, Inc. through a Schedule 13G filing.

The Vanguard Group has filed a Schedule 13G, revealing a beneficial ownership of 5.13% in Monte Rosa Therapeutics Inc. as of December 31, 2024.